Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients. The two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes. Clinicians will then have the comprehensive decision support for providing the right treatment and quality of care for their patients.
A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to research published today. A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which will help doctors and patients to decide on the best treatment options. They used samples from a previous trial funded by Cancer Research UK to look at the levels of two proteins, known as AREG and EREG, which are produced by some colorectal cancers. Algorithms driven by AI enabled the researchers to show that patients with higher levels of these proteins received significant benefit from a treatment which inhibits a different protein involved in cancer cell growth, known as EGFR. Of equal importance, patients with low levels of the proteins did not benefit from the treatment.
The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving. Predictive Oncology (NASDAQ: POAI) (POAI Profile) is in an enviable position in the precision-medicine industry due to its incredibly rich data set of more than 150,000 clinically validated cases on its molecular information platform, with 30,000-plus specific to ovarian cancer. The company is leveraging this unique database through Artificial Intelligence to provide the actionable insights needed to drive pharma R&D programs and improve patient outcomes. A data asset like this typically takes at least five years to fully validate and most competitors are only in the early stages of the process.
Coronavirus swabs and other key NHS tests are under threat after a supply chain failure at a major diagnostics company. Swiss pharmaceutical firm Roche said problems during a move to a new warehouse had caused a "very significant drop" in its processing capacity. A spokesperson said Covid-19 tests would be prioritised. One NHS trust has already advised its GPs to stop all non-urgent blood tests. In a statement, Roche said: "We deeply regret that there has been a delay in the dispatch of some products. "We are prioritising the dispatch of Covid-19 PCR [diagnostic] and antibody tests and doing everything we can to ensure there is no impact on the supply of these to the NHS." The company is one of two main suppliers of diagnostic testing equipment and materials in England. The affected warehouse is Roche's only distribution centre in the UK and covers the whole country. Dr Tom Lewis, lead clinician for pathology at North Devon District Hospital said his hospital's trust had sent out communications that all non-urgent bloods in the community should be stopped. Without rationing these non-urgent tests, he said, they would run out of swabs in "three to four days". Even with rationing, essential equipment could run short by next week, he said. Roche said it could take more than a fortnight to resolve the issue. Dr Lewis said perhaps most concerning was the shortage of electrolyte tests supplied by Roche since these were "the key test for critically ill patients" as well as being extremely commonly used by GPs to check people's medications were safe and not damaging their kidneys. One virologist in the Midlands tweeted that her service had not received Hepatitis C testing kits, and was now running short. Materials used in cancer diagnostics could also be affected. In a letter sent to NHS trusts, seen by the BBC, Roche said: "In September we moved from our old warehouse to a new automated warehouse capable of much higher volumes.
In today's era of personalised medicine, healthcare has evolved from mass treatments, which aren't effective for all patients, to medicines specifically targeted to patient groups based on companion diagnostic tests. Now, with the advent of more sophisticated digital technologies, personalised healthcare is entering a new phase, expanding from companion diagnostics to a more complex, holistic view of patient health generated from a wide variety of data sources. This web of data will require a new ecosystem of partnerships with healthcare and technology companies. "In the future, we will be using data for a variety of patient characteristics to determine the best combination of treatments to improve a person's overall healthcare," says Michele Pedrocchi, Head of Global Strategy and Business Development for Roche Diagnostics. Data about patients and medicines are already streaming in from many sources--in vivo diagnostics, lifestyle sensors, labs, electronic records, clinical trial data, genomic data, physicians, and patients themselves.